These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11755441)

  • 81. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).
    Doern GV; Jones RN; Pfaller MA; Kugler K
    Antimicrob Agents Chemother; 1999 Feb; 43(2):385-9. PubMed ID: 9925540
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
    Felmingham D; Farrell DJ; Reinert RR; Morrissey I
    J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges.
    Jacobs MR; Dagan R
    Semin Pediatr Infect Dis; 2004 Jan; 15(1):5-20. PubMed ID: 15175991
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antimicrobial resistance with bacterial causes of community-acquired respiratory tract infections in the United States.
    Doern GV
    Treat Respir Med; 2005; 4 Suppl 1():1-4. PubMed ID: 15846150
    [No Abstract]   [Full Text] [Related]  

  • 85. Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Kärpänoja P; Nyberg ST; Bergman M; Voipio T; Paakkari P; Huovinen P; Sarkkinen H;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2480-5. PubMed ID: 18443116
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Global surveillance through PROTEKT: the first year.
    Grüneberg RN
    J Chemother; 2002 Jul; 14 Suppl 3():9-16. PubMed ID: 12418556
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Susceptibility of common bacterial respiratory pathogens to antimicrobial agents in outpatients from South Backa District.
    Horvat O; Ukropina MM; Mijatović V; Sabo A
    Med Pregl; 2014; 67(3-4):71-7. PubMed ID: 24961047
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project.
    Washington JA
    Diagn Microbiol Infect Dis; 1996 Aug; 25(4):183-90. PubMed ID: 8937842
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antimicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens.
    García-Rodríguez JA; Baquero F; García de Lomas J; Aguilar L
    Infection; 1999; 27(4-5):265-7. PubMed ID: 10885840
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.
    Kiffer CR; Pignatari AC
    BMC Infect Dis; 2011 Oct; 11():286. PubMed ID: 22026724
    [TBL] [Abstract][Full Text] [Related]  

  • 91. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
    Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
    J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Correlations between the level of bacterial resistance and the rate of clinical efficiency in the therapy of community-acquired respiratory tract infections].
    Slănină AM; Filip O; Felea D; Cosmescu A; Petroaie A; Barbacariu L; Novac O; Manole M; Silvia M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):416-22. PubMed ID: 21495346
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Bacteria isolated from chronic upper and lower respiratory tract infections and the associated therapeutic strategies--in paranasal sinusitis].
    Suzuki K
    Kansenshogaku Zasshi; 2006 Jan; 80(1):13-8. PubMed ID: 16519120
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antimicrobial resistance of bacterial agents of the upper respiratory tract of school children in Buea, Cameroon.
    Ndip RN; Ntiege EA; Ndip LM; Nkwelang G; Akoachere JF; Akenji T N
    J Health Popul Nutr; 2008 Dec; 26(4):397-404. PubMed ID: 19069618
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece, 2009-2012.
    Maraki S; Papadakis IS
    ScientificWorldJournal; 2014; 2014():941564. PubMed ID: 24592201
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
    Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Antibiotic selection for the treatment of pediatric upper respiratory tract infections and the detection rate of drug-resistant strains].
    Tomiyama M
    Nihon Jibiinkoka Gakkai Kaiho; 2004 Feb; 107(2):156-68. PubMed ID: 15032006
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bacteria Etiological Agents Causing Lower Respiratory Tract Infections and Their Resistance Patterns.
    Khan S; Priti S; Ankit S
    Iran Biomed J; 2015; 19(4):240-6. PubMed ID: 26220641
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections.
    Jones RN
    Diagn Microbiol Infect Dis; 1997; 27(1-2):21-8. PubMed ID: 9127102
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Changing pattern of respiratory pathogens due to the development of antibacterial agents].
    Matsumoto K
    Nihon Saikingaku Zasshi; 1988 Jul; 43(4):809-20. PubMed ID: 3148770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.